Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Bioscientia Medicina : Journal of Biomedicine and Translational Research Bioscientia Medicina : Journal of Biomedicine and Translational Research
Elvira Yusri
Department of Clinical Pathology and Laboratory Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Neuroscience

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Differences in Average Albumin Levels in Coronavirus Disease 2019 (COVID-19) Survivor and Non-Survivor Patients: A Single Center Observational Study at Dr. M. Djamil General Hospital, Padang, Indonesia Doan Atrya; Rikarni; Elvira Yusri
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 9 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i9.1062

Abstract

Background: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 infection triggers a systemic inflammatory response that can lead to a decrease in serum albumin levels. A more severe inflammatory response in non-survivor COVID-19 patients may correlate with a more significant decrease in albumin levels. This study aims to analyze differences in mean albumin levels in COVID-19 survivors and non-survivors. Methods: This cross-sectional analytical study involved 40 COVID-19 survivors and non-survivors treated at Dr. M. Djamil General Hospital Padang from July 2021 to September 2021. Serum albumin levels were checked using an automated clinical chemistry tool. Data analysis was carried out using the Mann-Whitney non-parametric test, with a significance level of p < 0.05. Results: The mean age of the study subjects was 49.4 (16.3) years, with the majority of cases occurring in men (67.5%). The median albumin levels in all COVID-19 patients, COVID-19 survivors, and COVID-19 non-survivors were 3.2 (2.20–5.00) g/dL, respectively; 4.1 (3.0–5.0) g/dL; and 2.9 (2.20–3.70) g/dL (p = 0.001). Conclusion: There is a significant difference in mean albumin levels between COVID-19 survivors and non-survivors. Lower albumin levels were found in non-survivor patients. Albumin can be a potential biomarker for predicting clinical outcomes of COVID-19 patients.
Differences in Average Albumin Levels in Coronavirus Disease 2019 (COVID-19) Survivor and Non-Survivor Patients: A Single Center Observational Study at Dr. M. Djamil General Hospital, Padang, Indonesia Doan Atrya; Rikarni; Elvira Yusri
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 9 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i9.1062

Abstract

Background: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 infection triggers a systemic inflammatory response that can lead to a decrease in serum albumin levels. A more severe inflammatory response in non-survivor COVID-19 patients may correlate with a more significant decrease in albumin levels. This study aims to analyze differences in mean albumin levels in COVID-19 survivors and non-survivors. Methods: This cross-sectional analytical study involved 40 COVID-19 survivors and non-survivors treated at Dr. M. Djamil General Hospital Padang from July 2021 to September 2021. Serum albumin levels were checked using an automated clinical chemistry tool. Data analysis was carried out using the Mann-Whitney non-parametric test, with a significance level of p < 0.05. Results: The mean age of the study subjects was 49.4 (16.3) years, with the majority of cases occurring in men (67.5%). The median albumin levels in all COVID-19 patients, COVID-19 survivors, and COVID-19 non-survivors were 3.2 (2.20–5.00) g/dL, respectively; 4.1 (3.0–5.0) g/dL; and 2.9 (2.20–3.70) g/dL (p = 0.001). Conclusion: There is a significant difference in mean albumin levels between COVID-19 survivors and non-survivors. Lower albumin levels were found in non-survivor patients. Albumin can be a potential biomarker for predicting clinical outcomes of COVID-19 patients.
Co-Authors Doan Atrya Rikarni Rikarni